Monte Rosa Therapeutics, Inc. GLUE Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Bristol-Myers SquibbBMY

——

Nurix Therapeutics, Inc.NRIX

——

Kymera TherapeuticsKYMR

——

ImmunomeIMNM

——

Cogent Biosciences, Inc.COGT

——

Adaptive BiotechnologiesADPT

——

Other financials

Income statement

See full

Revenue$4.2M-95.0%

Operating income-$50.0M-214%

Net income-$44.5M-195%

EPS (diluted)-$0.45-179%

Balance sheet

See full

Cash & equivalents$159.9M+104%

Total debt$39.1M-6.7%

Total equity$521.9M+89.7%

Total assets$736.4M+87.3%

Cash flow

See full

Operating cash flow-$37.4M+17.9%

CapEx$1.9M+17.7%

Free cash flow-$39.2M+16.7%

Valuation

See full

Market cap$1.75B+361%

Enterprise value$1.63B+381%

P/S40.7×+38.4×

Profitability

See full

Operating margin-345.2%—

Net margin-302.6%—

FCF margin-45.8%-64.9pp

Returns & leverage

See full

Return on equity-32.6%—

Debt / equity0.1×-0.1×

Current ratio9.5×+3.9×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s software and technology licenses, net?: Monte Rosa Therapeutics, Inc. (GLUE) reported software and technology licenses, net of $832K in Q1 2026.
How has Monte Rosa Therapeutics, Inc.'s software and technology licenses, net changed year-over-year?: Monte Rosa Therapeutics, Inc.'s software and technology licenses, net increased by 89.1% year-over-year, from $440K to $832K.